Cinctive Capital Management’s Cytokinetics CYTK Stock Holding History

Cinctive Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.7M	Buy	137,838 +102,776	+293%	+$7.38M	0.43%	65
2026 Q1	$2.31M	Buy	35,062 +28,500	+434%	+$1.81M	0.15%	192
2025 Q4	$417K	Sell	6,562 -99,079	-94%	-$6.16M	0.02%	338
2025 Q3	$5.81M	Buy	+105,641	New	+$4.35M	0.28%	121
2025 Q2	–	Sell	-52,321	Closed	-$2.1M	–	398
2025 Q1	$2.1M	Buy	+52,321	New	+$2.4M	0.16%	156
2024 Q1	–	Sell	-15,000	Closed	-$1.25M	–	418
2023 Q4	$1.25M	Buy	+15,000	New	+$543K	0.08%	230

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cinctive Capital Management's CYTK Position: Q2 2026 in Review

Cinctive Capital Management increased its Cytokinetics (CYTK) stake by 293% in Q2 2026, buying an estimated $7.38M and bringing the position to 137,838 shares worth $11.7M. The position accounts for 0.43% of the portfolio, ranked #65.

Cinctive Capital Management first reported a position in CYTK in Q4 2023 and has held it in 6 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Cinctive Capital Management held 137,838 shares of Cytokinetics worth $11.7M as of Q2 2026.
Cinctive Capital Management bought 102,776 Cytokinetics shares in Q2 2026, an estimated $7.38M.
Cytokinetics made up 0.43% of Cinctive Capital Management's portfolio in Q2 2026, its #65 holding.
Cinctive Capital Management first reported a position in Cytokinetics in Q4 2023 and has held it in 6 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.